Breaking News, Collaborations & Alliances

Harbour BioMed, Otsuka Partner to Advance Bispecific T-Cell Engagers

Aim to develop next-generation biotherapeutics for the treatment of autoimmune diseases.

Author Image

By: Charlie Sternberg

Associate Editor

Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, has partnered with Otsuka Pharmaceutical Co., Ltd. to advance BCMAxCD3 bispecific T-cell engagers for the treatment of autoimmune diseases. Under the terms of the agreement, Otsuka is granted an exclusive license to develop, manufacture, and commercialize HBM7020, a BCMAxCD3 bispecific T-cell engager globally, excluding Greater China. In retu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters